Recent Publications
Battcock SM, Collier TW, Dong Z and Hirasawa K. Negative regulation of the alpha interferon-induced antiviral responses by the Ras/Raf/MEK pathway. (2006) J. Virol. 80(9):4422-4430
Popadiuk C, Xiong J, Wells M, Andrew P, Dankwa K, Hirasawa K, Lake B and Kao KR. Antisense suppression of Pygopus2 results in proliferative growth arrest of epithelial ovarian cancer. (2006) Clinical Cancer Research 12:2216-2223.
Norman KL, Hirasawa K, Yang AD, Shields MA, Lee PW. Reovirus oncolysis: the Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infection. (2004) Proc Natl Acad Sci U S A. 101(30):11099-104.
Loken SD, Norman KL, Hirasawa K, Nodwell M, Lester WM, Demetrick DJ. Morbidity in immunosuppressed (SCID/NOD) mice treated with reovirus (Dearing 3) as an anti-cancer biotherapeutic. (2004) Cancer Biol Ther. 3(8) 734-8.
Hirasawa K, Jun HS, Han H. and Yoon JW. Involvement of p38 mitogen-activated protein kinase in the replication of encephalomyocarditis virus. (2003) J. Virol., 77(10):5649-56.
Hirasawa K, Nishikawa SG, Norman KL and Lee PWK. Effective systematic reovirus therapy of metastatic cancer in immune-competent mice. (2003) Cancer Res., 63(2):348-53.
Alain T, Hirasawa K, Pon KJ, Nishikawa SG, Urbanski SJ, Auer Y, Luider J, Martin A, Johnston RN, Janowska-Wieczorek A, Lee PWK and Kossakowska AE. Reovirus therapy of lymphoid malignancies. (2002) Blood, 100(12):4146-53.
Norman KL, Coffey MC, Hirasawa K, Demetrick DJ, DiFrancesco LM, Strong JE and Lee PWK. Reovirus oncolysis of human breast cancer. (2002) Hum. Gene. Ther. 13 (20) 641-52.
Hirasawa K, Nishikawa SG, Norman KL, Alain T, Kossakowska AE and Lee PWK. Oncolytic reovirus against ovarian and colon cancer. (2002) Cancer Res. 62 (6) 1696-701. |